Data from previous studies have shown that NSCLC patients harboring uncommon EGFR mutations do not have consistently favorable responses to EGFR-TKIs comparing to those with common mutations [3, 7–9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.